Takotsubo cardiomyopathy, QT prolongation and arrhythmia care
Takotsubo cardiomyopathy is an acute and usually reversible form of myocardial injury that may follow intense emotional or physical stress. Its ECG pattern can mimic acute coronary syndrome, while repolarisation abnormalities such as ST-segment change, T-wave inversion and marked QT prolongation can create an electrically unstable substrate. Clinical priorities are to exclude obstructive coronary disease, identify patients at risk of ventricular tachycardia or torsades de pointes, and avoid antiarrhythmic drugs that may worsen QT prolongation without a clear indication.
Recognition in Australia depends on access to definitive cardiac care. Tertiary hospitals in Sydney, Melbourne, Brisbane and Perth usually provide continuous monitoring and 24-hour coronary angiography, whereas patients in regional or remote areas may need telehealth, ambulance transfer or support from the Royal Flying Doctor Service. After diagnosis, unnecessary coronary-syndrome testing should be avoided, but recurrent syncope or unstable tachycardia requires urgent escalation through the 000 emergency system.
Most cases of Takotsubo cardiomyopathy recover over weeks to months, so treatment usually targets the precipitating stress, reversible electrical factors and symptoms rather than prolonged rhythm suppression. The difficult cases are those with torsades, sustained ventricular tachycardia, ventricular fibrillation, persistent QT prolongation or severe ventricular dysfunction, where the benefit of intensive therapy must be weighed against repolarisation prolongation and drug toxicity.
Recognising the arrhythmic phenotype
The arrhythmic phenotype is variable. Some patients have little ventricular dysfunction, while others develop apical, mid-ventricular or basal ballooning, dynamic outflow obstruction and intracavitary thrombus. ST elevation and T-wave inversion may be regional and do not reliably identify a coronary culprit. Troponin release is generally modest relative to shock, but coronary angiography remains necessary when acute coronary syndrome cannot be excluded on clinical and ECG grounds.
QT lengthening often develops with the early ECG changes and may be most pronounced when the heart rate slows. Ventricular ectopy is common, and early reports of sudden cardiac arrest often involved polymorphic ventricular tachycardia degenerating into ventricular fibrillation. Torsades de pointes is less frequent but particularly relevant when QTc is prolonged, potassium is low or several QT-prolonging medicines are combined. Out-of-hospital arrest, sustained arrhythmia and cardiogenic shock identify a higher-risk phenotype.
Severe infection and the physiological stress that follows it can also precipitate stress-related myocardial injury. The journal's account of arrhythmias after COVID-19 provides useful context for assessing new palpitations, syncope or QT changes after severe illness. Viral inflammation, hypoxia, fever, electrolyte disturbance and medication exposure may all contribute, so arrhythmia should not automatically be attributed to residual cardiac injury without reviewing the timeline and conducting targeted investigation.
Measuring and explaining QT prolongation
QT should be measured from the start of the QRS complex to the end of the T wave, using a lead with a clean T-wave offset and averaging several beats. The QT interval shortens as heart rate rises, and Bazett's formula overcorrects at high rates and undercorrects at low rates. A Fridericia correction or another clinically validated approach may be more informative in tachycardia. QTc values should be interpreted alongside the preceding RR interval rather than as stand-alone numbers.
Several factors can compound acquired long-QT risk in Takotsubo cardiomyopathy: female sex, bradycardia, hypokalaemia or hypomagnesaemia, acute myocardial injury and heart failure. Congenital long-QT syndrome may be unmasked by the stress event or by treatment. Review antiarrhythmics, antibiotics, antipsychotics, antiemetics, antidepressants, methadone and combination products. Australian prescribers should check current Therapeutic Goods Administration product information, Australian Prescriber advice and interaction resources rather than relying on memory.
A QTc above 500 ms is a common high-risk marker, particularly with ectopy, syncope or pauses, but no single threshold guarantees safety. Values of 480–500 ms deserve attention when several risk factors coexist. Torsades can occur at shorter values in vulnerable patients, while some marked QT prolongations never produce arrhythmia. Serial ECGs, heart rate, potassium, magnesium, medication timing and the presence of U waves should therefore be documented together. Persistent prolongation after the acute phase warrants renewed investigation for congenital and drug-related causes.
Stratifying ventricular arrhythmia risk
Risk stratification begins with whether the patient has already sustained a malignant arrhythmia. Ventricular fibrillation, polymorphic ventricular tachycardia, torsades, sustained monomorphic ventricular tachycardia or syncope are strong warning signs. Patients with ongoing chest pain, shock, severe ventricular dysfunction or a rapidly changing ECG require continuous monitoring in a coronary care or intensive care setting. Lower-risk patients still need telemetry during the acute hospital period because the greatest risk often occurs early.
Echocardiography defines ventricular function, regional wall-motion abnormality, outflow obstruction and thrombus. Ambulatory ECG monitoring can quantify ectopic burden, pauses, paroxysmal atrial fibrillation and ventricular tachycardia after stabilisation; event recorders are useful when symptoms are intermittent but too infrequent for continuous monitoring. Exercise testing or catecholamine provocation should not be used to provoke arrhythmia in the acute phase. Electrophysiology review is appropriate for recurrent sustained tachycardia, unexplained syncope or suspected arrhythmic syncope.
No validated score currently combines QTc, ventricular function and arrhythmia history into a single Takotsubo-specific treatment threshold. Risk estimates based on acute coronary syndrome or congenital long-QT syndrome also have important limitations. A practical high-risk profile combines QTc above 500 ms, torsades or polymorphic tachycardia, significant potassium or magnesium depletion, bradycardia, multiple QT-prolonging agents, severe ventricular dysfunction and prior cardiac arrest. This profile should trigger urgent rhythm-directed review, not automatic prescribing of a QT-prolonging antiarrhythmic.
Selecting antiarrhythmic therapy
The first treatment decision is haemodynamic. Pulseless ventricular tachycardia or ventricular fibrillation requires immediate defibrillation under Australian resuscitation protocols. Unstable tachycardia with a pulse requires synchronised cardioversion. Magnesium sulfate, heart-rate acceleration or overdrive pacing may be needed for pause-dependent torsades, while potassium should be corrected promptly. These measures address the electrical emergency; antiarrhythmic medicines are supportive and must never delay shock or pacing.
For stable ventricular ectopy or recurrent ventricular tachycardia, beta-blockade is often the preferred pharmacologic option when blood pressure and heart rate permit, especially where catecholamine excess or continuing emotional stress is suspected. It should be used cautiously with shock, bradycardia, conduction disease or decompensated heart failure. Magnesium and potassium correction are central when torsades is present. Lidocaine may be considered for ventricular arrhythmia when beta-blockade is unsuitable, although evidence specific to Takotsubo cardiomyopathy remains limited.
Amiodarone and sotalol deserve particular caution because both can prolong QT. Sotalol should not be used to treat torsades and is generally unsuitable in marked QT prolongation. Amiodarone is not a routine response to isolated premature ventricular contractions, and its hypotensive effect can be problematic during shock. It may still have a role in shock-resistant ventricular fibrillation or ventricular tachycardia under advanced resuscitation protocols, with close ECG and electrolyte monitoring. Flecainide and propafenone are inappropriate during active structural dysfunction or coronary disease without specialist assessment.
Catheter ablation has no routine role during the index admission because the myocardial substrate is usually transient. It can be considered for persistent or recurrent ventricular tachycardia after recovery, or exceptionally for a severe ectopic burden despite medical therapy. Evidence summarised for idiopathic PVC ablation assumes a structurally normal ventricle and cannot simply be applied to active Takotsubo cardiomyopathy. Any decision to ablate should therefore follow reassessment of ventricular function and the ECG phenotype by an electrophysiologist.
Acute care and longitudinal follow-up
Acute care also includes treating the trigger, providing carefully titrated haemodynamic support and avoiding unnecessary fluid overload in patients with impaired contraction. Vasopressors may be needed in shock, but catecholamine excess can aggravate arrhythmia. Oxygen should be reserved for hypoxaemia. Anticoagulation should be individualised according to ventricular dysfunction, apical akinesis, atrial fibrillation, prior thromboembolism and bleeding risk; Takotsubo cardiomyopathy does not automatically require lifelong anticoagulation.
Long-term antiarrhythmic therapy is rarely indicated. Most patients receive a beta-blocker for recurrent arrhythmia, angina, hypertension or heart failure, with the indication and dose reviewed as ventricular function recovers. Persistent ventricular tachycardia despite correction of reversible causes, ventricular fibrillation or severe ventricular dysfunction months after the acute event warrants electrophysiology referral. A permanent implantable cardioverter-defibrillator is generally reserved for selected survivors of ventricular fibrillation or very high-risk persistent disease, not transient risk alone.
At discharge, provide a written plan for new palpitations, syncope, chest pain and breathlessness, including when to call 000 and when to contact the treating cardiologist. Repeat ECGs, electrolytes and echocardiography help confirm recovery; persistent QT prolongation, ventricular ectopy or conduction abnormalities need targeted review. In rural districts, specialist follow-up can be combined with local cardiology services and telehealth. Medication decisions should account for current Pharmaceutical Benefits Scheme listings, community pharmacy availability and TGA-approved product information.
For clinicians, document QTc, heart rate, electrolytes and every QT-prolonging medicine at admission and again before discharge. Use continuous monitoring when the ECG or ventricular function is concerning, stabilise the patient first and involve electrophysiology early if malignant arrhythmia occurs rather than waiting for formal ventricular recovery.
For trainees and researchers, the open-access collections of the Journal of Arrhythmia provide current material for refining these decisions. Read the linked papers, compare their recommendations with local protocols and share this article with colleagues managing acute chest pain, syncope or heart failure in Australian hospitals.